Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes

Journal of Controlled Release

Volumn 165, Issue 3, 2013, Pages 163-172

  Arranz, A ^a   Reinsch, C ^b   Papadakis, K A ^a   Dieckmann, A ^b   Rauchhaus, U ^b   Androulidaki, A ^a   Zacharioudaki, V ^a   Margioris, A N ^a   Tsatsanis, C ^a   Panzner, S ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b Novosom AG   (Germany)

Author keywords

Antisense oligonucleotides; CD40; Cell specific delivery; Crohn's disease; Keywords; TNBS colitis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDES; CD40; CELL-SPECIFIC DELIVERY; CROHN'S DISEASE; KEYWORDS; TNBS COLITIS;

CELL CULTURE; CELL PROLIFERATION; FLOW CYTOMETRY; HISTOLOGY; LIPOSOMES; MACROPHAGES; MAMMALS; ORGANIC ACIDS; PH; PHYSIOLOGY;

DISEASES;

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; LIPOSOME; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; ENTERITIS; FLOW CYTOMETRY; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CHEMOKINE CXCL10; COLITIS; FEMALE; INTERLEUKIN-6; LIPOSOMES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES, ANTISENSE; T-LYMPHOCYTES; TRINITROBENZENESULFONIC ACID;

EID: 84871393568     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.11.008     Document Type: Article

References (39)

1. K.A. Papadakis, and S. Tabibzadeh Diagnosis and misdiagnosis of inflammatory bowel disease Gastrointest. Endosc. Clin. N. Am. 12 2002 433 449
2. I.J. Fuss, F. Heller, M. Boirivant, F. Leon, M. Yoshida, S. Fichtner-Feigl, Z. Yang, M. Exley, A. Kitani, R.S. Blumberg, P. Mannon, and W. Strober Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis J. Clin. Invest. 113 2004 1490 1497
3. W. Strober, I. Fuss, and P. Mannon The fundamental basis of inflammatory bowel disease J. Clin. Invest. 117 2007 514 521
4. J.H. Cho The genetics and immunopathogenesis of inflammatory bowel disease Nat. Rev. Immunol. 8 2008 458 466
5. A. Bhushan, and L.R. Covey CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes Immunol. Res. 24 2001 311 324
6. S. Fujieda, K. Zhang, and A. Saxon IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specific isotype switch: switching to gamma 1, gamma 3, and gamma 4, but not gamma 2 J. Immunol. 155 1995 2318 2328
7. M.F. Mackey, R.J. Barth Jr., and R.J. Noelle The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells J. Leukoc. Biol. 63 1998 418 428
8. C.S. Subauste, M. Wessendarp, R.U. Sorensen, and L.E. Leiva CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer J. Immunol. 162 1999 6690 6700
9. E. Stuber, W. Strober, and M. Neurath Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion J. Exp. Med. 183 1996 693 698
10. Z. Liu, K. Geboes, S. Colpaert, L. Overbergh, C. Mathieu, H. Heremans, M. de Boer, L. Boon, G. D'Haens, P. Rutgeerts, and J.L. Ceuppens Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4 + T cells by blocking the CD40-CD154 interactions J. Immunol. 164 2000 6005 6014
11. Y. Cong, C.T. Weaver, A. Lazenby, and C.O. Elson Colitis induced by enteric bacterial antigen-specific CD4 + T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12 J. Immunol. 165 2000 2173 2182
12. S. Danese, M. Sans, F. Scaldaferri, A. Sgambato, S. Rutella, A. Cittadini, J.M. Pique, J. Panes, J.A. Katz, A. Gasbarrini, and C. Fiocchi TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease J. Immunol. 176 2006 2617 2624
13. A. Bai, P. Hu, J. Chen, X. Song, W. Chen, W. Peng, Z. Zeng, and X. Gao Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis Int. J. Colorectal Dis. 22 2007 625 635
14. C.F. Bennett, D. Kornbrust, S. Henry, K. Stecker, R. Howard, S. Cooper, S. Dutson, W. Hall, and H.I. Jacoby An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice J. Pharmacol. Exp. Ther. 280 1997 988 1000
15. M. Boirivant, F. Pallone, C. Di Giacinto, D. Fina, I. Monteleone, M. Marinaro, R. Caruso, A. Colantoni, G. Palmieri, M. Sanchez, W. Strober, T.T. MacDonald, and G. Monteleone Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis Gastroenterology 131 2006 1786 1798
16. D. Gao, A.H. Wagner, S. Fankhaenel, T. Stojanovic, S. Schweyer, S. Panzner, and M. Hecker CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis Gut 54 2005 70 77
17. A. Goto, Y. Arimura, Y. Shinomura, K. Imai, and Y. Hinoda Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis Inflamm. Bowel Dis. 12 2006 758 765
18. I.C. Lawrance, F. Wu, A.Z. Leite, J. Willis, G.A. West, C. Fiocchi, and S. Chakravarti A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B Gastroenterology 125 2003 1750 1761
19. M. Murano, K. Maemura, I. Hirata, K. Toshina, T. Nishikawa, N. Hamamoto, S. Sasaki, O. Saitoh, and K. Katsu Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis Clin. Exp. Immunol. 120 2000 51 58
20. K.J. Myers, S. Murthy, A. Flanigan, D.R. Witchell, M. Butler, S. Murray, A. Siwkowski, D. Goodfellow, K. Madsen, and B. Baker Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis J. Pharmacol. Exp. Ther. 304 2003 411 424
21. E. Andreakos, U. Rauchhaus, A. Stavropoulos, G. Endert, V. Wendisch, A.S. Benahmed, S. Giaglis, J. Karras, S. Lee, H. Gaus, C.F. Bennett, R.O. Williams, P. Sideras, and S. Panzner Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis Arthritis Rheum. 60 2009 994 1005
22. D. Peer, E.J. Park, Y. Morishita, C.V. Carman, and M. Shimaoka Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target Science 319 2008 627 630
23. V.D. Awasthi, D. Garcia, R. Klipper, B.A. Goins, and W.T. Phillips Neutral and anionic liposome-encapsulated hemoglobin: effect of postinserted poly(ethylene glycol)-distearoylphosphatidylethanolamine on distribution and circulation kinetics J. Pharmacol. Exp. Ther. 309 2004 241 248
24. E. Siepi, S. Lutz, S. Meyer, S. Panzner, An ion switch regulates fusion of charged membranes, Biophys. J. 100 (2011) 2412-2421.
25. C. Reinsch, E. Siepi, A. Dieckmann, and S. Panzner Strategies for the delivery of oligonucleotides in vivo J. Kurreck, Therapeutic Oligonucleotides 2008 The Royal Society of Chemistry Cambridge, UK 226 240
26. S.K. Klimuk, S.C. Semple, P.N. Nahirney, M.C. Mullen, C.F. Bennett, P. Scherrer, and M.J. Hope Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity J. Pharmacol. Exp. Ther. 292 2000 480 488
27. P.P. Van Veldhoven, and G.P. Mannaerts Inorganic and organic phosphate measurements in the nanomolar range Anal. Biochem. 161 1987 45 48
28. M. Saad, O.B. Garbuzenko, E. Ber, P. Chandna, J.J. Khandare, V.P. Pozharov, and T. Minko Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J. Control. Release 130 2008 107 114
29. H.R. Jiang, D.S. Gilchrist, J.F. Popoff, S.E. Jamieson, M. Truscott, J.K. White, and J.M. Blackwell Influence of Slc11a1 (formerly Nramp1) on DSS-induced colitis in mice J. Leukoc. Biol. 85 2009 703 710
30. J. Suttles, and R.D. Stout Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis Semin. Immunol. 21 2009 257 264
31. B.J. Voetberg, B.A. Garvy, H.K. Mayer, L.E. King, and P.J. Fraker Apoptosis accompanies a change in the phenotypic distribution and functional capacity of murine bone marrow B-cells chronically exposed to prednisolone Clin. Immunol. Immunopathol. 71 1994 190 198
32. A. Gabizon, and D. Papahadjopoulos Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc. Natl. Acad. Sci. U. S. A. 85 1988 6949 6953
33. C.D. Oja, S.C. Semple, A. Chonn, and P.R. Cullis Influence of dose on liposome clearance: critical role of blood proteins Biochim. Biophys. Acta 1281 1996 31 37
34. M. Marques, S. Rodrigues, E. Mariz, J. Pinto, T. Videira, J. Brito, C. Reis, F. Simoes-Ventura, F. Magro, Severe gram positive bacterial infection in an ulcerative colitis patient treated with Infliximab, J. Crohns Colitis 4 (2011) 110-113.
35. K. Barczyk, J. Ehrchen, K. Tenbrock, M. Ahlmann, J. Kneidl, D. Viemann, J. Roth, Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3, Blood 116 (2010) 446-455.
36. A. Doganci, M.F. Neurath, and S. Finotto Mucosal immunoregulation: transcription factors as possible therapeutic targets Curr. Drug Targets Inflamm. Allergy 4 2005 565 575
37. A.M. Jamieson, S. Yu, C.H. Annicelli, R. Medzhitov, Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection, Cell Host Microbe 7 (2010) 103-114.
38. P. Rutgeerts, S. Vermeire, and G. Van Assche Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 56 2007 453 455
39. S.M. Flechner, L. Zhou, I. Derweesh, B. Mastroianni, K. Savas, D. Goldfarb, C.S. Modlin, V. Krishnamurthi, and A. Novick The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients Transplantation 76 2003 1729 1734